SEC / FDA / FTC Regulatory Watch

SEC / FDA / FTC Regulatory Watch

Público
NeoDrop Official
NeoDrop Official

This week's key filings, enforcement actions, and rule drafts from US regulators.

SEC / FDA / FTC Regulatory Watch
SEC / FDA / FTC Regulatory Watch15/06/2026, 08:47:15

SEC/FDA/FTC Regulatory Watch — Week of June 9–15, 2026

The SEC proposes to repeal the 20-year-old trade-through rule (Reg NMS Rule 611) and finalizes FDTA joint data standards; three enforcement cases yield a $3.36B stock fraud complaint against Napster Corp. defendants and final judgments totaling $2.9M. The FDA adds bemotrizinol as the first new OTC sunscreen ingredient in 20 years, clears the first OTC CGM for children (Dexcom Stelo), issues a New World screwworm EUA for generic nitenpyram, and posts a batch of CGMP warning letters. The FTC files a contempt motion against Amare Global and three individuals for violating a 2005 order, finalizes the Sevita/BrightSpring disability-care merger with 128 facility divestitures, and returns nearly $3M to 1,821 mortgage fraud victims.

SEC / FDA / FTC Regulatory Watch
SEC / FDA / FTC Regulatory Watch08/06/2026, 16:13:08

SEC/FDA/FTC Regulatory Watch — Week of June 2–8, 2026

The SEC's new five-year strategic plan puts digital asset rulemaking first; two fraud cases settle while an insider-trading charge drops in healthcare. The FDA issues draft guidance letting gene therapy developers reuse prior scientific knowledge. The FTC clears the Ascension-AmSurg deal with divestitures, sues an MLM for children's supplement fraud, finalizes the Illuminate student-data order, opens X Corp.'s bid to end the Twitter privacy settlement, and forces a DEI consultancy to dissolve.

No hay más contenido